Parathyroid hormone activates adhesion in bone marrow stromal precursor cells.

Area of Science:

• Bone Biology
• Cell Adhesion Mechanisms
• Osteoporosis Therapeutics

Background:

• Parathyroid hormone (PTH) is used to treat osteoporosis by enhancing bone formation.
• The precise mechanisms by which PTH stimulates bone formation remain unclear.
• Osteoblasts, the cells responsible for bone formation, originate from bone marrow stromal precursors known as colony-forming units-fibroblastic (CFU-F).

Purpose of the Study:

• To investigate the early effects of PTH on CFU-F adhesion to bone.
• To elucidate the molecular pathways involved in PTH-mediated CFU-F adhesion.

Main Methods:

• Murine bone marrow cells were treated with PTH in vitro and in vivo.
• CFU-F adhesion was quantified by measuring adherent cells after incubation.
• The role of integrins, interleukin-6, cyclic AMP, nitric oxide, and prostaglandins was assessed using specific inhibitors and agonists.

Main Results:

• PTH administration in vivo caused a rapid reduction in ex vivo recoverable CFU-F.
• In vitro, PTH significantly increased CFU-F adhesion to surfaces within 24 hours.
• PTH-induced adhesion was dependent on prostaglandin E(2) and inhibited by indomethacin, but not mediated by integrins, IL-6, cAMP, or nitric oxide.

Conclusions:

• PTH rapidly promotes the adhesion of CFU-F to bone surfaces, likely via prostaglandin pathways.
• This enhanced adhesion represents a potential early mechanism underlying the anabolic effects of PTH on bone.
• Targeting CFU-F adhesion could offer new therapeutic strategies for osteoporosis.